Antibiotic resistance is a global threat and challenge that encompasses broad political, social and economic implications.
According to a recent EMEA report, resistance among Gram-positive and Gram-negative bacteria is already reaching 25% or more in several EU Member States. The most recent concern is the emergence of Gram-negative bacilli expressing the New Delhi metallo-beta-lactamase (NDM-1), which are resistant to all available antibiotics.
Despite these worrying facts, the late clinical stage antibiotic pipeline is very limited, indeed at its lowest point since the discovery of penicillin in 1928. Furthermore, recent changes in the regulatory expectations and standards for conducting trials of new antibacterial agents have meant current methods of conducting some specialized types of clinical trials are becoming inadequate.
The conference will address:
Global trends in infectious disease strategies - Identifying infectious disease threats, commercial opportunities, challenges facing antibiotic drug development and the role of the EC in funding antimicrobial research
Responding to multi-resistant organisms - Addressing the threat of carbapenemase producing enterobacterial strains, novel antibiotics to combat MDR organisms and the role of molecular diagnostics in treating MDR organisms, improving therapy and patient outcomes
Novel antimicrobial therapeutic approaches & areas - Investigate the next generation of antimicrobial therapeutics and learn from case studies and development strategies
Vaccine, anti-viral and anti-fungal developments - Trends in vaccine development, the need, opportunities and approaches for novel antifungal therapies and a new paradigm for treating infections and disease caused by HCMV
This conference will build upon a strong scientific reputation, featuring key leaders in the field of antibiotic resistance and drug development, case study focused presentations with a practical theme enabling you to learn from the best.